Robigo
Robigo engineers biological crop-protection solutions that use targeted microbes to control plant pathogens while preserving beneficial organisms.
UndisclosedSeries A
ParticipantIV
Illumina Ventures
illuminaventures.com ↗Activity from announced rounds
Activity in this selectioncape-fear-biocapital-89f4b680
Illumina Ventures invests in genomics and precision health, supporting companies that turn biological research into products and services.
Investment focus
The firm describes its role as building an ecosystem around advances in human health. Its published portfolio spans therapeutic development, enabling research technologies and biological applications.
Activity recorded by RoundOS
RoundOS examples include Encoded Therapeutics’ gene-regulation medicines, SonoThera’s gene-delivery platform and Syntax Bio’s cell-therapy technology. Robigo adds biological crop protection to the recorded activity. These are selected financings in the database, not an exhaustive portfolio.
Sources
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $441.4M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionEncoded Therapeutics Inc.
Encoded develops precision gene therapies for neurological disorders, led by ETX101, a gene-regulation therapy for people with SCN1A-positive Dravet syndrome.
$275MSeries F
ParticipantSyntax Bio
Develops cell therapies using proprietary Cellgorithm platform for regenerative medicine
$14.4MSeries A+
Role not disclosedSonoThera
Develops ultrasound-mediated nonviral genetic medicines
$125MSeries B
Role not disclosedLightcast
Develops functional single-cell analysis tools and platforms for life science research
$27MUndisclosed
Role not disclosed